Tristel (TSTL) Trading update summary

Financial performance highlights

• Revenues increased by 10% to £51.1m for FY 2026, compared to £46.5m in FY 2025.

• Adjusted EBITDA margin remained above the 25% target.

• Adjusted profit before tax grew 14% to at least £11.5m, slightly exceeding market expectations.

• Cash balances rose to £16.0m as of 30 June 2026, up from £12.8m the previous year.

• The company remains debt-free and cash generative, supporting ongoing overseas expansion.

Strategic and operational updates

• Continues to meet performance targets of double-digit revenue growth and strong EBITDA margins.

• Welcoming a new CEO, Chris Lee, effective 1 August, to drive further growth and international expansion.

• Employs approximately 270 people across 16 subsidiaries, selling into over 40 countries.

Business model and market position

• Focuses on infection prevention products using proprietary chlorine dioxide chemistry.

• Recognized as a market leader in manual decontamination of medical devices and sustainable surface disinfection.

• Targets progressive year-on-year dividend growth, supported by robust cash generation.